Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080011
Chunk: 64

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 64
---
 1 trigger price     |     | $          | 2,500.00 |   |     | $2,500.00 to $6,400.00 |
| Tranche 2 trigger price     |     | $          | 3,000.00 |   |     | $3,000.00 to $7,700.00 |
| Contractual term (in years) |     |            |     2.65 |   |     | 3.60 to 4.00           |
| Volatility                  |     |            |      100 | % |     | 90%                    |
| Risk-free interest rate     |     |            |     3.82 | % |     | 4.20% to 4.33%         |

<div align='center'>27</div>

The classification of the fair value of the earnout liability and derivative
liabilities and the change in the fair value measurement using significant inputs (Level 3) for the six months ended June 30, 2025 (Successor),
for the period from January 1, 2024 through February 13, 2024 (Predecessor), and February 14, 2024 through December 31, 2024 for the Company
is presented below:

| Preferred stock warrant liability (Predecessor): |     | Level 1 |   |     | Level 2 |   |     | Level 3 |            |   |     | Total |            |   |
|:-------------------------------------------------|:----|:--------|:--|:----|:--------|:--|:----|:--------|-----------:|:--|:----|:------|-----------:|:--|
| Balance at December 31, 2023                     |     | $       | - |     | $       | - |     | $       |    320,117 |   |     |       |    320,117 |   |
| Reclassification of warrant liability to equity  |     |         | - |     |         | - |     |         |   (320,117 | ) |     |       |   (320,117 | ) |
| Balance at February 13, 2024                     |     | $       | - |     | $       | - |     | $       |          - |   |     | $     |          - |   |
| Earnout liability (Success